GoAI
Get started
WuXi Biologics (Cayman) Inc. logo

WuXi Biologics (Cayman) Inc.

2269.HK

HKSEHealthcareBiotechnology

Open in GoAI

Latest quote

HK$52.20

+HK$3.60 · +7.41%

Aug 25, 4:08 PM HKT

2269.HK company overview

Regular session · HKT · Market data may be delayed.

Company profile

Company website

Headquartered in Wuxi, China, and established in 2014, WuXi Biologics (Cayman) Inc. delivers a comprehensive, integrated suite of services spanning the entire biologics lifecycle, from initial discovery through development to large-scale manufacturing. The company's operations have a global footprint, serving clients across the People's Republic of China, North America, Europe, and other international regions. Its diversified offerings also include specialized consultation in biopharmaceutical technology, international sales contracting, the development and deployment of advanced testing methodologies, and robust marketing and sales support. Furthermore, WuXi Biologics is involved in providing dedicated biologics clinical and manufacturing services, the production and distribution of various medical products, contract development and manufacturing (CDMO) for vaccines and associated businesses, and acting as a supplier of key materials. The firm maintains strategic partnerships with notable entities such as ImmuneOncia Therapeutics, Legochem Biosciences Inc., Worg Pharma, OncoC4, and Exelixis Inc.

Industry
Biotechnology
Sector
Healthcare
Headquarters
CN
CEO
Zhisheng Chen
Listed since
Jun 13, 2017
Employees
13,252

Market position

52-week range

Current HK$52.20

Open
HK$52.20
Previous close
HK$48.60
Volume
0
0× average
Average volume
32.11M
Average daily volume
Market cap
216.29B HKD
Beta
0.6
Market reference 1
50-day average
HK$38.9632
+33.97% above average
200-day average
HK$35.8976
+45.41% above average

Financials

Financial snapshot

Latest / TTM

Valuation & yield

Enterprise value
113.3B CNY
P/E (TTM)
37.62×
P/B (TTM)
3.99×
P/S (TTM)
8.51×
EV / EBITDA
14.3×
Earnings yield
4.11%
Free cash flow yield
2.34%
Dividend yield
0.00%

Profitability & efficiency

Gross margin
45.98%
Operating margin
30.47%
Net margin
22.53%
Return on equity
10.38%
Return on assets
7.70%
Return on invested capital
9.26%

Financial health

Debt / equity
0.07×
Current ratio
3.14×
Altman Z-score
11.77
Piotroski F-score
9 of 9

Financial statements

Margin trends

Profitability as a percentage of reported revenue.

Gross marginOperating marginNet margin
Gross, operating, and net margin trends50%38%27%15%Gross margin, FY2021: 46.93%Gross margin, FY2022: 44.04%Gross margin, FY2023: 40.08%Gross margin, FY2024: 40.97%Gross margin, FY2025: 45.98%Operating margin, FY2021: 30.98%Operating margin, FY2022: 28.44%Operating margin, FY2023: 26.12%Operating margin, FY2024: 26.63%Operating margin, FY2025: 30.47%Net margin, FY2021: 32.93%Net margin, FY2022: 28.95%Net margin, FY2023: 19.96%Net margin, FY2024: 17.97%Net margin, FY2025: 22.53%FY2021FY2022FY2023FY2024FY2025
Gross margin FY2021 46.93%. Gross margin FY2022 44.04%. Gross margin FY2023 40.08%. Gross margin FY2024 40.97%. Gross margin FY2025 45.98%. Operating margin FY2021 30.98%. Operating margin FY2022 28.44%. Operating margin FY2023 26.12%. Operating margin FY2024 26.63%. Operating margin FY2025 30.47%. Net margin FY2021 32.93%. Net margin FY2022 28.95%. Net margin FY2023 19.96%. Net margin FY2024 17.97%. Net margin FY2025 22.53%.

Income trends

Revenue

21.79B CNY+16.68%

Operating income

6.64B CNY+33.49%

Net income

4.91B CNY+46.25%
Income trends across reported periods23.65B CNY16.21B CNY8.77B CNY1.33B CNYRevenue, FY2021: 10.29B CNYRevenue, FY2022: 15.27B CNYRevenue, FY2023: 17.03B CNYRevenue, FY2024: 18.68B CNYRevenue, FY2025: 21.79B CNYOperating income, FY2021: 3.19B CNYOperating income, FY2022: 4.34B CNYOperating income, FY2023: 4.45B CNYOperating income, FY2024: 4.97B CNYOperating income, FY2025: 6.64B CNYNet income, FY2021: 3.39B CNYNet income, FY2022: 4.42B CNYNet income, FY2023: 3.4B CNYNet income, FY2024: 3.36B CNYNet income, FY2025: 4.91B CNYFY2021FY2022FY2023FY2024FY2025
Revenue FY2021 10.29B CNY. Revenue FY2022 15.27B CNY. Revenue FY2023 17.03B CNY. Revenue FY2024 18.68B CNY. Revenue FY2025 21.79B CNY. Operating income FY2021 3.19B CNY. Operating income FY2022 4.34B CNY. Operating income FY2023 4.45B CNY. Operating income FY2024 4.97B CNY. Operating income FY2025 6.64B CNY. Net income FY2021 3.39B CNY. Net income FY2022 4.42B CNY. Net income FY2023 3.4B CNY. Net income FY2024 3.36B CNY. Net income FY2025 4.91B CNY.
Metric (CNY)FY2025FY2024FY2023FY2022FY2021
Revenue21.79B CNY18.68B CNY17.03B CNY15.27B CNY10.29B CNY
Cost of goods sold11.77B CNY11.02B CNY10.21B CNY8.54B CNY5.46B CNY
Gross profit10.02B CNY7.65B CNY6.83B CNY6.72B CNY4.83B CNY
Research and development860.13M CNY766.44M CNY792.58M CNY682.82M CNY501.58M CNY
Selling, general, and administrative2.45B CNY2.15B CNY1.79B CNY1.43B CNY1B CNY
Operating expenses3.38B CNY2.68B CNY2.38B CNY2.38B CNY1.64B CNY
Interest income384.37M CNY350.37M CNY219.18M CNY107.48M CNY58.03M CNY
Interest expense139.36M CNY157.59M CNY158.49M CNY64.38M CNY39.19M CNY
Depreciation and amortization1.28B CNY1.44B CNY1.17B CNY800.67M CNY481.78M CNY
Operating income6.64B CNY4.97B CNY4.45B CNY4.34B CNY3.19B CNY
Net income4.91B CNY3.36B CNY3.4B CNY4.42B CNY3.39B CNY

Company facts updated Aug 25, 2026.

Earnings

EPS beat rate
55%
6 beats, 5 misses, 0 met estimates
Average EPS surprise
+6.23%
11 comparable reports
Latest EPS result
0.67
Estimate 0.52 · Beat by 28.90%

EPS: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly EPS actual values compared with estimates0.860.640.420.2Q3 '23MissQ1 '24BeatQ3 '24MissQ1 '25MissQ3 '25BeatQ1 '26MissQ3 '26BeatQ1 '27Estimate
Q3 2023, reported Aug 23, 2023: actual 0.564, estimate 0.594, surprise -5.05%, Miss. Q1 2024, reported Mar 27, 2024: actual 0.288, estimate 0.275, surprise +4.87%, Beat. Q3 2024, reported Aug 21, 2024: actual 0.375, estimate 0.44, surprise -14.63%, Miss. Q1 2025, reported Mar 24, 2025: actual 0.24, estimate 0.469, surprise -48.87%, Miss. Q3 2025, reported Aug 19, 2025: actual 0.599, estimate 0.49, surprise +22.20%, Beat. Q1 2026, reported Mar 24, 2026: actual 0.679, estimate 0.705, surprise -3.69%, Miss. Q3 2026, reported Aug 25, 2026: actual 0.669, estimate 0.519, surprise +28.90%, Beat. Q1 2027, reported Mar 23, 2027: actual —, estimate 0.816, surprise —, Comparison unavailable.

Revenue: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly Revenue actual values compared with estimates16.58B13.78B10.97B8.16BQ3 '23BeatQ1 '24MissQ3 '24BeatQ1 '25BeatQ3 '25BeatQ1 '26BeatQ3 '26BeatQ1 '27Estimate
Q3 2023, reported Aug 23, 2023: actual 9.18B HKD, estimate 8.8B HKD, surprise +4.36%, Beat. Q1 2024, reported Mar 27, 2024: actual 9.45B HKD, estimate 11.36B HKD, surprise -16.76%, Miss. Q3 2024, reported Aug 21, 2024: actual 9.21B HKD, estimate 8.97B HKD, surprise +2.70%, Beat. Q1 2025, reported Mar 24, 2025: actual 10.75B HKD, estimate 10.3B HKD, surprise +4.33%, Beat. Q3 2025, reported Aug 19, 2025: actual 10.89B HKD, estimate 10.64B HKD, surprise +2.34%, Beat. Q1 2026, reported Mar 24, 2026: actual 13.25B HKD, estimate 13.17B HKD, surprise +0.61%, Beat. Q3 2026, reported Aug 25, 2026: actual 13.6B HKD, estimate 13.25B HKD, surprise +2.64%, Beat. Q1 2027, reported Mar 23, 2027: actual —, estimate 15.94B HKD, surprise —, Comparison unavailable.

Corporate actions

Corporate action history

Stock split

Effective Nov 16, 2020

3:1

2269.HK peers

WuXi AppTec Co., Ltd. logo

2359.HK

WuXi AppTec Co., Ltd.

HK$204.2

+3.29%

Jiangsu Hengrui Pharmaceuticals Co.,Ltd logo

1276.HK

Jiangsu Hengrui Pharmaceuticals Co.,Ltd

HK$46.50

+0.09%

BeOne Medicines AG logo

6160.HK

BeOne Medicines AG

HK$223.2

+0.81%

Hansoh Pharmaceutical Group Company Limited logo

3692.HK

Hansoh Pharmaceutical Group Company Limited

HK$31.58

+1.67%

Innovent Biologics, Inc. logo

1801.HK

Innovent Biologics, Inc.

HK$100.1

+0.60%

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. logo

6990.HK

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.

HK$523.5

+0.10%

ETFs holding 2269.HK

Funds reporting this stock among their holdings, ordered by reported position size.

Vanguard Total International Stock ETF logoVanguard Total International Stock ETFVXUS
Market value
272.35M
Weight
0.04%
AUM
646.2B USD
Expense ratio
0.05%
Price / 1D
$88.12+1.06%
Vanguard FTSE Emerging Markets ETF logoVanguard FTSE Emerging Markets ETFVWO
Market value
259.18M
Weight
0.15%
AUM
162.3B USD
Expense ratio
0.06%
Price / 1D
$60.64+1.12%
iShares Core MSCI Emerging Markets ETF logoiShares Core MSCI Emerging Markets ETFIEMG
Market value
248.36M
Weight
0.16%
AUM
158.05B USD
Expense ratio
0.09%
Price / 1D
$81.89+1.74%
Avantis Emerging Markets Equity ETF logoAvantis Emerging Markets Equity ETFAVEM
Market value
70.61M
Weight
0.25%
AUM
27.58B USD
Expense ratio
0.33%
Price / 1D
$94.73+1.74%
JPMorgan BetaBuilders Developed Asia Pacific ex-Japan ETF logoJPMorgan BetaBuilders Developed Asia Pacific ex-Japan ETFBBAX
Market value
67.99M
Weight
0.99%
AUM
6.89B USD
Expense ratio
0.19%
Price / 1D
$65.80+1.15%
Global X China Biotech ETF (HKD) logoGlobal X China Biotech ETF (HKD)2820.HK
Market value
61.94M
Weight
10.69%
AUM
701.08M HKD
Expense ratio
0.68%
Price / 1D
HK$75.18+2.56%
iShares MSCI Emerging Markets ETF logoiShares MSCI Emerging Markets ETFEEM
Market value
55.25M
Weight
0.18%
AUM
30.71B USD
Expense ratio
0.72%
Price / 1D
$67.25+1.72%
iShares MSCI China ETF logoiShares MSCI China ETFMCHI
Market value
54M
Weight
0.86%
AUM
6.22B USD
Expense ratio
0.59%
Price / 1D
$55.12+0.35%

Continue in GoAI

Research 2269.HK

research.disclaimer